Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.66 |
| ▸ | ECE1 | P42892 | 9/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429294 | 1.00 | ACE (0.66) | ACEECE1OPRM1OPRD1ALOX15 | |
| SCHEMBL30053213 | 0.92 | ACE (0.64) | ACEECE1OPRM1OPRD1ALOX15 | |
| SCHEMBL30052764 | 0.90 | KDM4E (0.62) | ACEECE1OPRM1OPRD1ALOX15 | |
| SCHEMBL30051470 | 0.90 | ECE1 (0.66) | ACEECE1OPRM1OPRD1ALOX15 | |
| SCHEMBL30051300 | 0.89 | ACE (0.60) | ACEECE1OPRM1OPRD1ALOX15 | |
| SCHEMBL1228369 | 0.89 | ACE (0.78) | ACEECE1ALOX15 | |
| SCHEMBL2488765 | 0.89 | ACE (0.78) | ACEECE1ALOX15 | |
| SCHEMBL9235805 | 0.89 | ACE (0.78) | ACEECE1ALOX15 | |
| SCHEMBL9235801 | 0.89 | ACE (0.78) | ACEECE1ALOX15 | |
| SCHEMBL29400177 | 0.89 | ACE (0.78) | ACEECE1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0234186-B1 | USE OF OLIGOPEPTIDS FOR THE TREATMENT OF CEREBRAL DISORDERS | Fresenius AG (DE) | 1991-11-06 | — | — | EP | disclosed |
| EP-0234186-A1 | Use of oligopeptids for the treatment of cerebral disorders | Fresenius AG (DE) | 1987-09-02 | — | — | EP | disclosed |